Roth Capital Resumes Neogenomics (NEO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil prices set for fourth straight monthly gains as tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts NEO Hot Sheet
Price: $17.16 -4.29%
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 49 | New: 9
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 49 | New: 9
Join SI Premium – FREE
Roth Capital resumed coverage on Neogenomics (NASDAQ: NEO) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.
Shares of Neogenomics closed at $8.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neogenomics (NEO) PT Raised to $24 at Piper Sandler
- Maxim Group Starts Nasus Pharma Ltd (NSRX) at Buy
- Jefferies Starts AbCellera Biologics (ABCL) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
